Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | STK4 | Q13043 | 1/20 | 0.39 |
| ▸ | STK3 | Q13188 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.37 |
| ▸ | PKD1 | P98161 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5128492 | 0.84 | GRM5 (0.43) | GRM5MAP3K14PKD1 | |
| SCHEMBL5129376 | 0.83 | GRM5 (0.46) | GRM5KDM4EMAPTMAP3K14 | |
| SCHEMBL5129146 | 0.81 | GRM5 (0.47) | GRM5AVPR1ANPSR1 | |
| SCHEMBL5118732 | 0.81 | GRM5 (0.44) | GRM5MAP3K14 | |
| SCHEMBL5119696 | 0.81 | ALDH1A1 (0.50) | GRM5KDM4E | |
| SCHEMBL5129798 | 0.80 | GRM5 (0.43) | GRM5MAP3K14 | |
| SCHEMBL15214296 | 0.78 | GRM5 (0.70) | GRM5MALT1TRPV1AVPR1A | |
| SCHEMBL5115831 | 0.77 | GRM5 (0.43) | GRM5MAP3K14 | |
| SCHEMBL5128572 | 0.77 | GRM5 (0.49) | GRM5MAPTMAP3K14 | |
| SCHEMBL5129624 | 0.77 | GRM5 (0.45) | GRM5MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | GRM5, GRIK5, GRM1 | GRM5 1/4885MALT1 4704/4885TRPV1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.